´ëÇѺñ´¢±âÁ¾¾çÇÐȸ The 21st KUOS Multidisciplinary Conference(2ÀÏÂ÷) : 2023-03-25
±³À°ÀÏÀÚ : 2023-03-25
±³À°Àå¼Ò : ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ
±³À°ÁÖÁ¦ : The 21st KUOS Multidisciplinary Conference(2ÀÏÂ÷)
ÁÖÃÖ±â°ü : ´ëÇѺñ´¢±âÁ¾¾çÇÐȸ
´ã´çÀÚ : ±èÀºÁÖ
¿¬¶ôó : 02-704-8574
À̸ÞÀÏ : app@app2010.com
±³À°Á¾·ù : ºñ´¢ÀÇÇаú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 5Á¡
Áö¿ª : ¼¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 30,000¿ø
ºñ°í Àü¹®ÀÇ: 30,000¿ø / Àü°øÀÇ, ±ºÀÇ°ü, °£È£»ç: 20,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 08:10~08:40 Registration ()
±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 08:40~09:00 President¡¯s Welcome ()
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:00~09:20 Introducing PI-QUAL (Prostate Imaging Quality) Score Àå¿ø(ÀüºÏÀÇ´ë ¿µ»óÀÇÇаú)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:20~09:40 AI (Artificial Intelligence) application ±èÂù±³(¼º±Õ°üÀÇ´ë ¿µ»óÀÇÇаú)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:40~09:57 Role of metastatectomy in RCC: Where do we stand? ¹ÚÁø¼º(À»ÁöÀÇ´ë ºñ´¢ÀÇÇаú)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 09:57~10:14 Which approach is better for 1st line treatment in mRCC ½Å»óÁØ(¿¬¼¼ÀÇ´ë Á¾¾ç³»°ú)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:14~10:30 SBRT on renal cell carcinoma: an overview of technical aspects and biological rationale ÀÓÁÖÇÑ(ÀÎÇÏÀÇ´ë Á¾¾ç³»°ú)
ÈÞ½Ä 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:30~10:50 Break ()
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 10:50~11:20 Genomic Testing and treatment with PARP-inhibitors in Patients with MetastaticCastration-resistant Prostate Cancer: A Pragmatic Guide for Clinicians in view of the recent data Axel Merseburger MD PhD((University Hospital Schleswig-HolsteinLübeck Germany)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:20~11:37 Role of the prostate- and/or metastasis-directed radiation for oligometastatic HSPC ±Ç¹Î¼±(¾ÆÁÖÀÇ´ë Á¾¾ç³»°ú)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:37~11:54 Surgery for micro-metastatic HSPC diagnosed by PSMA PET/CT after definitive treatment ±è¼ºÈ¯(°¡Å縯ÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 11:54~12:10 Update in the systemic management for low volume mHSPC ÀÌÈ¿Áø(Ãæ³²ÀÇ´ë Á¾¾ç³»°ú)
½Ä»ç 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 12:10~13:40 Lunch ()
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 13:40~14:00 Role of surgery in metastatic PPGL ±è¿Ï¼®(ÀÌÈÀÇ´ë ºñ´¢ÀÇÇаú)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:00~14:20 Newer diagnostic & therapeutic modalities in PPGL ±è¿¬ÁÖ(¿ï»êÀÇ´ë ¹æ»ç¼±Á¾¾çÇаú)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:20~14:50 PSMA Targeted Radioligand Therapy: Current Status and Future Directions Phillip Koo MD FACS(Division Chief of Diagnostic Imaging at the Banner MD Anderson Cancer Center in Arizona)
ÈÞ½Ä 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 14:50~15:10 Break ()
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:10~15:30 Kidney ÀÌÁ¤Çö(°í·ÁÀÇ´ë º´¸®°ú)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:30~15:50 Urinary bladder and prostate Ȳ¼öÇö(¼º±Õ°üÀÇ´ë º´¸®°ú)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 15:50~16:10 Treatment of Huge Non-muscle invasive bladder cancer without high grade ±¸ÀÚÇö(¼¿ïÀÇ´ë ºñ´¢ÀÇÇаú)
±³À°½Ã°£ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:10~16:30 Radiation therapy for BCG-unresponsive NMIBC ±èÀÎÈ£(°¡Å縯ÀÇ´ë Á¾¾ç³»°ú)
±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:30~16:40 Çмú»ó ½Ã»ó½Ä ()
±âŸ 03-25 ¼¼Á¾´ëÇб³ ±¤°³Åä°ü ÁöÇÏ2Ãþ ÄÁº¥¼Ç¼¾ÅÍ 16:40~17:10 Æóȸ ¹× ÃÑȸ ()